Cees G. M. Kallenberg
University of Groningen
101 Papers
757 Citations
Cees G. M. Kallenberg is an academic researcher from University of Groningen. The author has contributed to research in topics: Anti-neutrophil cytoplasmic antibody & Medicine. The author has an hindex of 48, co-authored 94 publications. Previous affiliations of Cees G. M. Kallenberg include University Medical Center Groningen.
Chat about Author
Papers
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
John Charles Jennette,Ronald Falk,P. A. Bacon,Neil Basu,Maria C. Cid,Franco Ferrario,Luis Felipe Flores-Suárez,W. L. Gross,Loïc Guillevin,E. C. Hagen,Gary S. Hoffman,David Jayne,Cees G. M. Kallenberg,Peter Lamprecht,Carol A. Langford,Raashid Luqmani,Alfred Mahr,Eric L. Matteson,Peter A. Merkel,Peter A. Merkel,Seza Ozen,Charles D. Pusey,Niels Rasmussen,Andrew J. Rees,David G. I. Scott,Ulrich Specks,John H. Stone,Kei Takahashi,Richard A. Watts +28 more
TL;DR: 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides J. Watts; Arthritis & Rheumatism
5.7K
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone,Peter A. Merkel,Robert Spiera,Philip Seo,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Anthony M. Turkiewicz,Nadia K. Tchao,Lisa Webber,Linna Ding,Lourdes P. Sejismundo,Kathleen Mieras,David Weitzenkamp,David Ikle,Vicki Seyfert-Margolis,Mark Mueller,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Ulrich Specks +28 more
TL;DR: Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease.
EULAR Recommendations for the management of primary small and medium vessel vasculitis
Chetan Mukhtyar,Loïc Guillevin,Maria C. Cid,Bhaskar Dasgupta,K de Groot,Wolfgang L. Gross,Thomas H. Hauser,B Hellmich,David Jayne,Cees G. M. Kallenberg,Peter A. Merkel,Heiner Raspe,Carlo Salvarani,Dgi Scott,Coen A. Stegeman,Richard A. Watts,Kerstin Westman,James Witter,Halil Yazici,Raashid Luqmani +19 more
TL;DR: On the basis of evidence and expert consensus, recommendations have been made for the evaluation, investigation, treatment and monitoring of patients with small and medium vessel vasculitis for use in everyday clinical practice.
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
George Bertsias,John P. A. Ioannidis,John Boletis,Stefano Bombardieri,Ricard Cervera,C. Dostal,J Font,Inge-Magrethe Gilboe,F. Houssiau,Twj Huizinga,David A. Isenberg,Cees G. M. Kallenberg,Munther A. Khamashta,J.C. Piette,Matthias Schneider,Matthias Schneider,Josef S Smolen,Gunnar Sturfelt,Angela Tincani,R. van Vollenhoven,Caroline Gordon,Dimitrios T. Boumpas +21 more
TL;DR: Recommendations for the management of SLE were developed using an evidence-based approach followed by expert consensus with high level of agreement among the experts.
797
Efficacy of Remission-Induction Regimens for ANCA-associated Vasculitis
Ulrich Specks,Peter A. Merkel,Philip Seo,Robert Spiera,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Barri J. Fessler,Linna Ding,Lisa Viviano,Nadia K. Tchao,Deborah Phippard,Adam Asare,Noha Lim,David Ikle,Brett Jepson,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Mark Mueller,Lourdes P. Sejismundo,Kathleen Mieras,John H. Stone +30 more
TL;DR: In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remissions over the course of 18 months.